Population pharmacokinetic models have traditionally used empirical mammillary compartmental models of drug disposition, 1, 2 but these mammillary models are not ideal in their description of hepatic first-pass effects and plasma protein binding.
Clearly, there is a need to develop more physiologically-relevant, long-term culture model systems for assessing toxicity, conducting in vitro-in vivo extrapolation (IVIVE) and supporting development of physiologically-based pharmacokinetic (PBPK) models of chemical disposition and toxicity.
Neuroticism figures prominently in the widely accepted Big Five model of personality disposition (a model that considers five factors openness to experience, conscientiousness, extraversion, agreeableness, as well as neuroticism to produce its assessment).
In addition to modeling of drug disposition (PK) pathways, we emphasize the need for modeling of effect (PD) pathways and the use of a multidisciplinary infrastructure for data-sharing.
In the future, data obtained through in vivo MD will be useful in resolving uncertainties in biotransformation rate and capacity parameters, which are central to fish PB-TK modeling of chemical disposition.
A population-based estimate of exposure should account for the intrinsic heterogeneity (variability) in the population, both in the modeling of the disposition of the chemical in the body, and in the description of the exposure conditions.
Based on results of the sensitivity analysis and iterative model fitting, the initial model of midazolam disposition in pregnancy was revised such that ka was increased to 2.5 h–1, Vmax,H was increased 1.6-fold, and Vmax,GW was left unchanged from the healthy volunteer model.
As the ultimate outcome of the SBSP modeling, the kinetics of disposition is expressed as a nonlinear disposition function of properties, with adjustable coefficients containing the biological and chemical attributes, which do not vary under given experimental conditions.
In this review, we discuss strategies in the applications of both in vitro and in vivo experimental models of drug metabolism and disposition.
The main outcome of the model-free techniques is the prediction of disposition or effects of untested chemicals.
